European Society of Breast Imaging (EUSOBI) guidelines on the management of axillary lymphadenopathy after COVID-19 vaccination : 2023 revision
(2023) In Insights into Imaging 14(1).- Abstract
Axillary lymphadenopathy is a common side effect of COVID-19 vaccination, leading to increased imaging-detected asymptomatic and symptomatic unilateral axillary lymphadenopathy. This has threatened to negatively impact the workflow of breast imaging services, leading to the release of ten recommendations by the European Society of Breast Imaging (EUSOBI) in August 2021. Considering the rapidly changing scenario and data scarcity, these initial recommendations kept a highly conservative approach. As of 2023, according to newly acquired evidence, EUSOBI proposes the following updates, in order to reduce unnecessary examinations and avoid delaying necessary examinations. First, recommendation n. 3 has been revised to state that breast... (More)
Axillary lymphadenopathy is a common side effect of COVID-19 vaccination, leading to increased imaging-detected asymptomatic and symptomatic unilateral axillary lymphadenopathy. This has threatened to negatively impact the workflow of breast imaging services, leading to the release of ten recommendations by the European Society of Breast Imaging (EUSOBI) in August 2021. Considering the rapidly changing scenario and data scarcity, these initial recommendations kept a highly conservative approach. As of 2023, according to newly acquired evidence, EUSOBI proposes the following updates, in order to reduce unnecessary examinations and avoid delaying necessary examinations. First, recommendation n. 3 has been revised to state that breast examinations should not be delayed or rescheduled because of COVID-19 vaccination, as evidence from the first pandemic waves highlights how delayed or missed screening tests have a negative effect on breast cancer morbidity and mortality, and that there is a near-zero risk of subsequent malignant findings in asymptomatic patients who have unilateral lymphadenopathy and no suspicious breast findings. Second, recommendation n. 7 has been revised to simplify follow-up strategies: in patients without breast cancer history and no imaging findings suspicious for cancer, symptomatic and asymptomatic imaging-detected unilateral lymphadenopathy on the same side of recent COVID-19 vaccination (within 12 weeks) should be classified as a benign finding (BI-RADS 2) and no further work-up should be pursued. All other recommendations issued by EUSOBI in 2021 remain valid.
(Less)
- author
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- COVID-19 vaccines, Lymphadenopathy, Magnetic resonance imaging, Mammography, Ultrasonography (breast)
- in
- Insights into Imaging
- volume
- 14
- issue
- 1
- article number
- 126
- publisher
- Springer
- external identifiers
-
- pmid:37466753
- scopus:85165376652
- ISSN
- 1869-4101
- DOI
- 10.1186/s13244-023-01453-2
- language
- English
- LU publication?
- yes
- id
- 7275811f-6dfe-4242-bf91-1fa8d46bddad
- date added to LUP
- 2023-08-28 15:42:57
- date last changed
- 2024-04-20 02:07:18
@article{7275811f-6dfe-4242-bf91-1fa8d46bddad,
abstract = {{<p>Axillary lymphadenopathy is a common side effect of COVID-19 vaccination, leading to increased imaging-detected asymptomatic and symptomatic unilateral axillary lymphadenopathy. This has threatened to negatively impact the workflow of breast imaging services, leading to the release of ten recommendations by the European Society of Breast Imaging (EUSOBI) in August 2021. Considering the rapidly changing scenario and data scarcity, these initial recommendations kept a highly conservative approach. As of 2023, according to newly acquired evidence, EUSOBI proposes the following updates, in order to reduce unnecessary examinations and avoid delaying necessary examinations. First, recommendation n. 3 has been revised to state that breast examinations should not be delayed or rescheduled because of COVID-19 vaccination, as evidence from the first pandemic waves highlights how delayed or missed screening tests have a negative effect on breast cancer morbidity and mortality, and that there is a near-zero risk of subsequent malignant findings in asymptomatic patients who have unilateral lymphadenopathy and no suspicious breast findings. Second, recommendation n. 7 has been revised to simplify follow-up strategies: in patients without breast cancer history and no imaging findings suspicious for cancer, symptomatic and asymptomatic imaging-detected unilateral lymphadenopathy on the same side of recent COVID-19 vaccination (within 12 weeks) should be classified as a benign finding (BI-RADS 2) and no further work-up should be pursued. All other recommendations issued by EUSOBI in 2021 remain valid. <br/></p>}},
author = {{Schiaffino, Simone and Pinker, Katja and Cozzi, Andrea and Magni, Veronica and Athanasiou, Alexandra and Baltzer, Pascal A.T. and Camps Herrero, Julia and Clauser, Paola and Fallenberg, Eva M. and Forrai, Gabor and Fuchsjäger, Michael H. and Gilbert, Fiona J. and Helbich, Thomas and Kilburn-Toppin, Fleur and Kuhl, Christiane K. and Lesaru, Mihai and Mann, Ritse M. and Panizza, Pietro and Pediconi, Federica and Sardanelli, Francesco and Sella, Tamar and Thomassin-Naggara, Isabelle and Zackrisson, Sophia and Pijnappel, Ruud M.}},
issn = {{1869-4101}},
keywords = {{COVID-19 vaccines; Lymphadenopathy; Magnetic resonance imaging; Mammography; Ultrasonography (breast)}},
language = {{eng}},
number = {{1}},
publisher = {{Springer}},
series = {{Insights into Imaging}},
title = {{European Society of Breast Imaging (EUSOBI) guidelines on the management of axillary lymphadenopathy after COVID-19 vaccination : 2023 revision}},
url = {{http://dx.doi.org/10.1186/s13244-023-01453-2}},
doi = {{10.1186/s13244-023-01453-2}},
volume = {{14}},
year = {{2023}},
}